CSIMarket
 
Vigil Neuroscience Inc   (VIGL)
Other Ticker:  
 
 
Price: $3.3900 $-0.09 -2.586%
Day's High: $3.5 Week Perf: 2.11 %
Day's Low: $ 3.33 30 Day Perf: 24.63 %
Volume (M): 68 52 Wk High: $ 12.74
Volume (M$): $ 230 52 Wk Avg: $6.74
Open: $3.50 52 Wk Low: $2.53



 Market Capitalization (Millions $) 132
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -79
 Cash Flow (TTM) (Millions $) -147
 Capital Exp. (TTM) (Millions $) 1

Vigil Neuroscience Inc
Vigil Neuroscience Inc is a biotechnology company that specializes in delivering innovative solutions for brain health. The company's primary focus is on developing advanced diagnostic tools and personalized therapies for neurological disorders. Vigil Neuroscience combines cutting-edge technologies, such as artificial intelligence and machine learning, with extensive knowledge in neuroscience to provide accurate and efficient solutions for brain-related conditions. Their goal is to improve patient outcomes and revolutionize the field of neuroscience by providing transformative treatments for various neurological disorders.


   Company Address: 100 Forge Road, Watertown 2472 MA
   Company Phone Number: 254-4445   Stock Exchange / Ticker: NASDAQ VIGL
   VIGL is expected to report next financial results on March 20, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Unveiling the Clinical Overlap and Genetic Testing Challenges in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): Insights from ACTRIMS 2024

Published Thu, Feb 29 2024 9:05 PM UTC

Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) is a rare neurodegenerative disorder that presents with variable symptoms, often resembling multiple sclerosis (MS). Genetic testing plays a crucial role in definitive ALSP diagnosis, but patients encounter various barriers in accessing this essential tool. This article aims to explore the clinic...

Product Service News

Unveiling Vigil Neuroscience: Advancing Breakthroughs in Neurological Therapies

Published Wed, Jan 3 2024 9:30 PM UTC

As we close the chapter on 2023 and look forward to what lies ahead in the field of neuroscience, Vigil Neuroscience shines a light on its remarkable achievements and highlights exciting milestones slated for 2024. With a focus on developing innovative therapies for debilitating neurological disorders, Vigil Neuroscience is making significant progress towards transforming th...

Vigil Neuroscience Inc

Vigil Neuroscience Inc's Existing Expenditures Experience Significant Growth in Fiscal Year Ending September 30th, 2023



This financial news report covers the challenging financial situation faced by Vigil Neuroscience Inc during the reporting cycle from July to September 30, 2023. The report focuses on the company's operating deficit, widening net loss, and declining stock performance. Additionally, market observers are keenly awaiting signs of revenue growth and analysing the company's strategies to establish a steady product line. The report concludes with information on the anticipated release of the next financial results.
Operating Deficit and Net Loss:
Vigil Neuroscience Inc has reported an operating deficit of $-22.321 million for the reporting period, representing a significant deterioration from the same period in 2022 when the deficit stood at $-17.637 million. The widening operating deficit illustrates the company's financial challenges. Concurrently, the net loss incurred during the same period has increased to $-20.495 million compared to $-17.500 million in the third quarter of 2022.

Vigil Neuroscience Inc

Vigil Neuroscience Inc. Emerges as a Prominent Player in Biotech & Pharmaceuticals Sector with Encouraging Financial Results for Q2 2023

Understanding VIGL's Operating Shortfall and Financial Results
The Biotechnology & Pharmaceuticals industry is known for being dominated by large companies. However, amidst their supremacy, there are a few overlooked businesses that also play a significant role in the market. One such company is Vigil Neuroscience Inc, commonly referred to as VIGL.
VIGL recently announced its financial results for the second quarter of 2023, revealing an operating shortfall of $-21.913 million. To fully comprehend the impact of these numbers, it's essential to put them into context by comparing them to previous fiscal periods. By doing so, we can gain a clearer understanding of the company's current financial standing.

Vigil Neuroscience Inc

Vigil Neuroscience Inc's Financial First Quarter Results are In! Discover the Ascension of a Hidden Gem in the Biotech Industry

The Biotechnology & Pharmaceuticals industry is known for its large companies dominating the sector. However, recently some investors have started paying attention to overlooked companies that have significant potential but often get unnoticed. One such company is Vigil Neuroscience Inc (VIGL), which reported an operating shortfall of $-20.775 million in the first quarter of 2023. Despite this shortfall, investors are optimistic about the company's future prospects.
Vigil Neuroscience Inc is a small business in the industry and has been struggling to generate revenue in recent years. However, the company is currently in the midst of a developing period, and investors are eagerly waiting for potential revenue sources to evolve. This optimism stems from the idea that Vigil Neuroscience Inc has a lot of potential, and it's only a matter of time before the company achieves profitability.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com